Search Result

No of hits: 233

    Universitätsklinik für Psychiatrie und Psychosomatik, Abteilung für Psychiatrie und Psychotherapie

  1. Detailinformationen: Biologisch-psychiatrische Forschung. Lieb K., Riemann D., Berger M.: Biologisch-psychiatrische Forschung. In: Gustav Fischer, Stuttgart, 1994.
  2. Detailinformationen: Cyclooxygenase-2 expression in rat microglia is induced by adenosine a(2a)-receptors. Fiebich B L, Biber K, Lieb K, Calker D v, Berger M, Bauer J, Gebicke-Härter PJ: Cyclooxygenase-2 expression in rat microglia is induced by adenosine a(2a)-receptors. Glia, 1996; 18: 152-160
  3. Detailinformationen: Das chronische Müdigkeitssyndrom ("chronic fatigue syndrome", CFS). Lieb K, Dammann G, Berger M, Bauer J: Das chronische Müdigkeitssyndrom ("chronic fatigue syndrome", CFS). Nervenarzt, 1996; 67: 711-720
  4. Detailinformationen: Demenzerkrankungen - Diagnose, Differentialdiagnose und Therapie. Rösler N, Hüll M, Lieb K, Wolf R, Berger M, Bauer J: Demenzerkrankungen - Diagnose, Differentialdiagnose und Therapie. Fortschr Med, 1996; 114: 351-356
  5. Detailinformationen: Effects of NSAIDs on IL-1ß -induced IL-6 mRNA and protein synthesis in human astrocytoma cells. Fiebich BL, Lieb K, Hüll M, Berger M, Bauer J: Effects of NSAIDs on IL-1ß -induced IL-6 mRNA and protein synthesis in human astrocytoma cells. Neuroreport, 1996; 7: 1209-1213
  6. Detailinformationen: Effects of substance P and selected other neuropeptides on the synthesis of interleukin-1? and interleukin-6 in human monocytes: a reexamination. Lieb K, Fiebich B L, Busse-Grawitz M, Hüll M, Berger M, Bauer J: Effects of substance P and selected other neuropeptides on the synthesis of interleukin-1? and interleukin-6 in human monocytes: a reexamination. J. Neuroimmunol., 1996; 67: 77-81
  7. Detailinformationen: Interleukin-1? uses common and distinct signaling pathways for induction of the interleukin-6 and tumor necrosis factor ? genes in the human astrocytoma cell line U373. Lieb K, Kaltschmidt C, Kaltschmidt K, et al.: Interleukin-1? uses common and distinct signaling pathways for induction of the interleukin-6 and tumor necrosis factor ? genes in the human astrocytoma cell line U373. J Neurochem, 1996; 66: 1496-1503
  8. Detailinformationen: Interleukin-1ß and tumor necrosis factor- induce expression of 1-antichymotrypsin in human astrocytoma cells by activation of nuclear factor-kappa. Lieb K, Fiebich B L, Schaller H, Berger M, Bauer J: Interleukin-1ß and tumor necrosis factor- induce expression of 1-antichymotrypsin in human astrocytoma cells by activation of nuclear factor-kappa. J Neurochem, 1996; 67: 2039-2044
  9. Detailinformationen: Interleukin-1ß uses common and distinct signaling pathways for induction of the interleukin-6 and tumor necrosis factor genes in the human astrocytoma cell line U373. Lieb K, Kaltschmidt C, Kaltschmidt K, Bäuerle PA, Berger M, Bauer J, Fiebich BL: Interleukin-1ß uses common and distinct signaling pathways for induction of the interleukin-6 and tumor necrosis factor genes in the human astrocytoma cell line U373. J Neurochem, 1996; 66: 1496-1503
  10. Detailinformationen: Interleukin-6 associated inflammatory processes in Alzheimer's disease: new therapeutic options. Hüll M, Fiebich B L, Lieb K, Strauss S, Berger M, Volk B, et al.: Interleukin-6 associated inflammatory processes in Alzheimer's disease: new therapeutic options. Neurobiol Aging, 1996; 17: 795-800
  11. Detailinformationen: Kurzlehrbuch Biologie. Lieb K: Kurzlehrbuch Biologie.Mediscript Verlag, 4. Auflage. Auflage , 1996.
  12. Detailinformationen: Kurzlehrbuch Psychiatrie. Brunnhuber S, Lieb K: Kurzlehrbuch Psychiatrie.Mediscript Verlag, 3. Auflage. Auflage , 1996.
  13. Detailinformationen: Microglia as a model of NSAID action in the brain. Fiebich B L, Lieb K, Pairet M, et al.: Microglia as a model of NSAID action in the brain. Eur. J. Clin. Pharmacol., 1996; 50: 541
  14. Detailinformationen: Neurobiologische Korrelate der Alzheimer-Krankheit.Spinale und zerebrale Prozesse. Rösler N, Hüll M, Lieb K, Bauer J: Neurobiologische Korrelate der Alzheimer-Krankheit. In: Spinale und zerebrale Prozesse. Einhorn-Presse-Verlag, 1996; 285-291.
  15. Detailinformationen: Pre- and postnatal development of dopaminergic neuron numbers in the male and female mouse midbrain. Lieb K, Andersen C, Lazarov N, Zienecker R, Urban I, Pilgrim C, Reisert I: Pre- and postnatal development of dopaminergic neuron numbers in the male and female mouse midbrain. Brain Res Dev Brain Res, 1996; 94: 37-43
  16. Detailinformationen: Preattentive information processing as measured by backward masking and texton detection tasks in adolescents at high genetic risk for schizophrenia. Lieb K, Denz E, Hess R, Schüttler R, Kornhuber HH, Schreiber H: Preattentive information processing as measured by backward masking and texton detection tasks in adolescents at high genetic risk for schizophrenia. Schizophr. Res., 1996; 21: 171-182
  17. Detailinformationen: Sex differentiation of rat hippocampal GABAergic neurons. Reisert I, Lieb K, Beyer C, Pilgrim C: Sex differentiation of rat hippocampal GABAergic neurons. Eur J Neurosci, 1996; 8: 1718-1724
  18. Detailinformationen: Sex-specific vulnerability of developing dopaminergic neurons. Pilgrim C, Lieb K, Reisert I: Sex-specific vulnerability of developing dopaminergic neurons. In: Tectum Verlag, 1996; 100-103.
  19. Detailinformationen: Depression, borna disease, and amantadine. Lieb K, Hufert F, Bechter K, Bauer J, Kornhuber J: Depression, borna disease, and amantadine. Lancet, 1997; 349: 958
  20. Detailinformationen: Die Beteiligung eines Interleukin-6-assoziierten Prozesses an der Pathogenese der Alzheimer-Demenz.Alzheimer-Krankheit. Hüll M, Rösler N, Lieb K, Fiebich B L, Berger M, Bauer J: Die Beteiligung eines Interleukin-6-assoziierten Prozesses an der Pathogenese der Alzheimer-Demenz. In: Rösler M, Retz W, Thome J (Hrsg.): Alzheimer-Krankheit. Beltz Deutscher Studien Verlag, 1997; 160-163.
  21. Detailinformationen: Expression and regulation of cyclooxygenase-2 in rat microglia. Bauer M K A, Lieb K, Schulze-Osthoff K, Berger M, Gebicke-Härter PC, Bauer J, Fiebich BL: Expression and regulation of cyclooxygenase-2 in rat microglia. Eur. J. Biochem., 1997; 243: 726-731
  22. Detailinformationen: Immunologische Systemerkrankungen als Differentialdiagnose in der Psychiatrie. Lieb K, Vaith P, Berger M, Bauer J: Immunologische Systemerkrankungen als Differentialdiagnose in der Psychiatrie. Nervenarzt, 1997; 68: 696-707
  23. Detailinformationen: No borna disease virus-specific RNA detected in blood from psychiatric patients in different regions of Germany. Lieb K, Hallensleben W, Czygan M, Stitz L, Staeheli P: No borna disease virus-specific RNA detected in blood from psychiatric patients in different regions of Germany. Lancet, 1997; 350: 1002
  24. Detailinformationen: Potent inhibition of interleukin-6 expression in human astrocytoma cell line by tenidap. Lieb K, Fiebich B L, Hüll M, Berger M, Bauer J: Potent inhibition of interleukin-6 expression in human astrocytoma cell line by tenidap. Cell Tissue Res., 1997; 288: 251-257
  25. Detailinformationen: Prostaglandin E2 induces interleukin-6 synthesis in human astrocytoma cells. Fiebich B L, Hüll M, Lieb K, Gyufko K, Berger M, Bauer J: Prostaglandin E2 induces interleukin-6 synthesis in human astrocytoma cells. J Neurochem, 1997; 68: 704-709
  26. Detailinformationen: The neuropeptide P activates transcription factor NF-kB and kB-dependent gene expression in human astrocytoma cells. Lieb K, Fiebich B L, Berger M, Bauer J, Schulze-Osthoff K: The neuropeptide P activates transcription factor NF-kB and kB-dependent gene expression in human astrocytoma cells. J. Immunol., 1997; 159: 4952-4958
  27. Detailinformationen: Borna disease virus as a cause of human neuropsychiatric disorders: fact or artefact? Lieb K, Czygan M, Bauer J, Berger M, Hallensleben W, Staeheli P: Borna disease virus as a cause of human neuropsychiatric disorders: fact or artefact? Eur Arch Psychiatry Clin Neurosci, 1998; 248: 146
  28. Detailinformationen: Borna Disease Virus - Depression durch Infektion? Lieb K, Sauder C, Czygan M, Hallensleben W, Staeheli P: Borna Disease Virus - Depression durch Infektion? Via medici, 1998; 5: 52-53
  29. Detailinformationen: Borna Disease Virus und psychiatrische Erkrankungen - Fakt oder Artefakt? Lieb K, Sauder C, Czygan M, Hallensleben W, Staeheli P: Borna Disease Virus und psychiatrische Erkrankungen - Fakt oder Artefakt? Deutsche Medizinische Wochenschrift, 1998; 123: 1217-1218
  30. Detailinformationen: Bornaviren - Ursache psychiatrischer Erkrankungen? Zum aktuellen Stand der Diskussion. Lieb K, Staeheli P: Bornaviren - Ursache psychiatrischer Erkrankungen? Zum aktuellen Stand der Diskussion. Ars medici, 1998; 17: 1077-1079
  31. Detailinformationen: Inflammatory mechanisms in Alzheimer's disease: Links between cytokine pathology and arachidonic acid metabolism. Bauer J, Hüll M, Lieb K, Fiebich BL: Inflammatory mechanisms in Alzheimer's disease: Links between cytokine pathology and arachidonic acid metabolism. Eur Arch Psychiatry Clin Neurosci, 1998; 248: S24
  32. Detailinformationen: Interferon-alpha/beta induced changes in cerebral glucose metabolism as measured by positron emission tomography. Lieb K, Jüngling F, Brandt C, Lücking CH, Berger M, Bauer J: Interferon-alpha/beta induced changes in cerebral glucose metabolism as measured by positron emission tomography. Eur Arch Psychiatry Clin Neurosci, 1998; 248: 135
  33. Detailinformationen: Mikroglia: Mechanismen der Aktivierung und Bedeutung bei der Pathogenese neuropsychiatrischer Erkrankungen. Gebicke-Härter PJ, Lieb K, Illes P, Berger M: Mikroglia: Mechanismen der Aktivierung und Bedeutung bei der Pathogenese neuropsychiatrischer Erkrankungen. Nervenarzt, 1998; 69: 752-762
  34. Detailinformationen: Potential link between interleukin-6 and arachidonic acid metabolism in Alzheimer`s disease. Fiebich BL, Hüll M, Lieb K, Schumann G, Berger M, Bauer J: Potential link between interleukin-6 and arachidonic acid metabolism in Alzheimer`s disease. J Neural Transm, 1998; 53: 269-278
  35. Detailinformationen: Regulation and inhibition of cytokine synthesis in astrocytes: Basci steps for the identification of new antiinflammatory drugs for the treatment of Alzheimer's disease. Lieb K, fiebich BL, Hüll M, Schumann G, Berger M, Bauer J: Regulation and inhibition of cytokine synthesis in astrocytes: Basci steps for the identification of new antiinflammatory drugs for the treatment of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci, 1998; 248: 101
  36. Detailinformationen: Substance P and histamine induce interleukin-6 expression in human astrocytoma cells by a mechanism involving protein kinase C and Nuclear Factor-IL-6. Lieb K, Schaller H, Bauer J, Berger M, Schulze-Osthoff K, Fiebich BL: Substance P and histamine induce interleukin-6 expression in human astrocytoma cells by a mechanism involving protein kinase C and Nuclear Factor-IL-6. J Neurochem, 1998; 70: 1577-1583
  37. Detailinformationen: Antibacterial activity of hyperforin from St. John's wort. Fiebich BL, Heinrich M, Langosch JM, Kammerer N, Lieb K: Antibacterial activity of hyperforin from St. John's wort. The Lancet, 1999; 354: 777
  38. Detailinformationen: Anti-inflammatory substances - a new therapeutic option in Alzheimer's disease. Hüll M, Fiebich BL, Schumann G, Lieb K, Bauer J: Anti-inflammatory substances - a new therapeutic option in Alzheimer's disease. Drug Discovery Today, 1999; 4: 275-282
  39. Detailinformationen: Borna disease virus in human brains with a rare from of hippocampal degeneration but not in brains of patients with common neuropsychiatric disorders. Czygan M, Hallensleben W, Hofer M, Pollak S, Sauder C, Blizer T, Blümcke I, Riederer P, Bogerts B, Falkai P, Schwarz MJ, Masliah E, Staeheli P, Hufert FT, Lieb K: Borna disease virus in human brains with a rare from of hippocampal degeneration but not in brains of patients with common neuropsychiatric disorders. J Infect Dis, 1999; 180: 1695-1699
  40. Detailinformationen: Borna-Disease-Virus - Ursache psychiatrischer Erkrankungen? Lieb K: Borna-Disease-Virus - Ursache psychiatrischer Erkrankungen? Deutsches Ärzteblatt, 1999; 96: 1422-1423
  41. Detailinformationen: Bornaviren und psychiatrische Erkrankungen: Zusammenhänge weiterhin unklar. Staeheli P, Lieb K: Bornaviren und psychiatrische Erkrankungen: Zusammenhänge weiterhin unklar. Mitteilungsblatt des Instituts für Medizinische Mikrobiologie und Immunologie, 1999; 3: 2
  42. Detailinformationen: Detection of interleukin-6 in the brains of Alzheimer's disease patients. Hüll M, Lieb K, Fiebich BL: Detection of interleukin-6 in the brains of Alzheimer's disease patients. Curr. Opin. Psychiatry, 1999; 12: S02-S01
  43. Detailinformationen: Impairment in preattentive visual processing patients with Parkinson's disease. Lieb K, Brucker S, Bach M, Els T, Lücking CH, Greenlee ME: Impairment in preattentive visual processing patients with Parkinson's disease. Brain, 1999; 122: 303-313
  44. Detailinformationen: Insomnia for 5 years. Lieb K, Maiwald M, Berger M, Voderholzer U: Insomnia for 5 years. The Lancet, 1999; 354: 1966
  45. Detailinformationen: NK-1-receptor antagonism as a new antidepressant strategy - molecular analysis of NK-1-receptor regulation in the CNS. Lieb K, Czygan M, Fiebich BL, Berger M: NK-1-receptor antagonism as a new antidepressant strategy - molecular analysis of NK-1-receptor regulation in the CNS. Pharmacopsychiat., 1999; 32: 195
  46. Detailinformationen: Potential link between Interleukin-6 and arachnidonic metabolism in Alzheimer's disease.Alzheimer's disease - from basic research to clinical application. Fiebich BL, Hüll M, Lieb K, Schumann G, Berger M, Bauer J: Potential link between Interleukin-6 and arachnidonic metabolism in Alzheimer's disease. In: Gertz HJ, Arendt T (Hrsg.): Alzheimer's disease - from basic research to clinical application. Springer Verlag, 1999; 269-279.
  47. Detailinformationen: Psychiatrie und Psychotherapie. Lieb K, Brunnhuber S: Psychiatrie und Psychotherapie.Urban und Fischer, 1999.
  48. Detailinformationen: Regulation of cyclooxygenase-2 in rat microglia: Role of MAP kinases ans spingomyelinases. Fiebich BL, Lieb K, Hüll M, Kreder D, Krönke M, Gebicke-Härter PJ: Regulation of cyclooxygenase-2 in rat microglia: Role of MAP kinases ans spingomyelinases. J Neurochem, 1999; 73: S79D
  49. Detailinformationen: Regulation of substance P-induced cytokine expression in astrocytes. Lieb K, Czygan M, Craig A, Fiebich BL: Regulation of substance P-induced cytokine expression in astrocytes. Exp Clin Endocrinol Diabetes, 1999; 107 (Suppl.): 39-40
  50. Detailinformationen: Substance P-receptor antagonists - a new strategy of antidepressant ans anxiolytic pharmacotherapy. Lieb K: Substance P-receptor antagonists - a new strategy of antidepressant ans anxiolytic pharmacotherapy. Pharmacopsychiat., 1999; 32: 195
  51. Detailinformationen: The neuropeptide substance P activates p38 MAP-kinase resulting in interleukin-6 expression independently from nuclear factor-kappa B. Craig A, Czygan M, Butcher RD, Lieb K, Fiebich BL: The neuropeptide substance P activates p38 MAP-kinase resulting in interleukin-6 expression independently from nuclear factor-kappa B. J Neurochem, 1999; 73: S153D
  52. Detailinformationen: The neuropeptide substance P activates p38 MAP-kinase that induces interleukin-6 expression in human astrocytoma cells independently from activation of nuclear factor-kappa B. Fiebich BL, Craig A, Butcher RD, Lieb K: The neuropeptide substance P activates p38 MAP-kinase that induces interleukin-6 expression in human astrocytoma cells independently from activation of nuclear factor-kappa B. Brain Res., 1999; 848: 25
  53. Detailinformationen: The non-steroidal anti-inflammatory drug tepoxalin inhibits interleukin-6 und alpha1-anti-chymotrypsin synthesis in astrocytes by preventing degradation of IkB-alpha. Fiebich BL, Hofer TJ, Lieb K, Hüll M, Butcher RD, Schumann G, Schulze-Osthoff K, Bauer J: The non-steroidal anti-inflammatory drug tepoxalin inhibits interleukin-6 und alpha1-anti-chymotrypsin synthesis in astrocytes by preventing degradation of IkB-alpha. Neuropharmacology, 1999; 38: 1325-1333
  54. Detailinformationen: Anti-inflammatory drugs: a hope for Alzheimer's disease? Hüll M, Lieb K, Fiebich BL: Anti-inflammatory drugs: a hope for Alzheimer's disease? Exp Opin Invest Drugs, 2000; 9 (4): 671-683
  55. Detailinformationen: Demonstration of borna disease virus nucleic acid in a patinet with chronic fatigue syndrome. Staeheli P, Lieb K, Czygan M, Sauder C, Schwemmle M: Demonstration of borna disease virus nucleic acid in a patinet with chronic fatigue syndrome. J Infect Dis, 2000; 181: 1860-1861
  56. Detailinformationen: Effects of caffeine and paracetamol alone or in combination with acetylsalicylic acid on PGE2-synthesis in rat microglial cells. Fiebich BL, Lieb K, Hüll M, Aicher B, Ryn v J, Pairet M, Engelhardt G: Effects of caffeine and paracetamol alone or in combination with acetylsalicylic acid on PGE2-synthesis in rat microglial cells. Neuropharmacology, 2000; 39: 2205-2213
  57. Detailinformationen: Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Jüngling FD, Ebert D, Gut O, Engelbrecht MA, Rasenack J, Nitzsche EU, Bauer J, Lieb K: Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Neuropsychopharmacol, 2000; 152: 383-389
  58. Detailinformationen: Protective role of neurotrophins in experimental inflammation of the rat gut. Reinshagen M, Rohm H, Steinkamp M, Lieb K, Geerling I, von Herbay A, Flämig G, Eysselein VE, Adler G: Protective role of neurotrophins in experimental inflammation of the rat gut. Gastroenterology, 2000; 119: 368-376
  59. Detailinformationen: Sleep deprivation and growth-hormone secretion. Lieb K, Reincke M, Riemann D, Voderholzer U: Sleep deprivation and growth-hormone secretion. Lancet, 2000; 356: 2096-2097
  60. Detailinformationen: Strategies to delay the onset of Alzheimer's disease.New approaches to drug development. Hüll M, Fiebich BL, Lieb K: Strategies to delay the onset of Alzheimer's disease. In: Jollès P (Hrsg.): New approaches to drug development. Birkhäuser Verlag, 2000; 211-225.
  61. Detailinformationen: Substanz P-Rezeptor-Antagonisten als neues antidepressives und anxiolytisches Wirkprinzip? Lieb K, Fiebich BL, Berger M: Substanz P-Rezeptor-Antagonisten als neues antidepressives und anxiolytisches Wirkprinzip? Nervenarzt, 2000; 71: 758-761
  62. Detailinformationen: The neuropeptide substance P activitates p38 MAP kinase resulting in interleukin-6 expression independently from nuclear factor-kappa B. Fiebich BL, Schleicher S, Butcher RD, Craig A, Lieb K: The neuropeptide substance P activitates p38 MAP kinase resulting in interleukin-6 expression independently from nuclear factor-kappa B. J Immunol, 2000: 5606-5611
  63. Detailinformationen: Borna disease virus - does it infect humans and cause psychiatric disorders? Lieb K, Staeheli P: Borna disease virus - does it infect humans and cause psychiatric disorders? J Clin Virol, 2001; 21: 119-127
  64. Detailinformationen: Bornavirus and psychiatric disorders - fact or fiction? Staeheli P, Lieb K: Bornavirus and psychiatric disorders - fact or fiction? J Med Microbiol, 2001; 50: 1-3
  65. Detailinformationen: Extrem ausgeprägte Insomnie im Rahmen einer cerebralen Whipple Erkrankung: Langzeitverlauf unter Therapie Voderholzer U, Riemann D, Gann H, Hornyak M, Berger M, Weske G, Lieb K: Extrem ausgeprägte Insomnie im Rahmen einer cerebralen Whipple Erkrankung: Langzeitverlauf unter Therapie Somnologie, 2001; 5: 56
  66. Detailinformationen: Inhibition of substance p-induced cytokine synthesis by St. John's wort extracts. Fiebich BL, Höllig A, Lieb K: Inhibition of substance p-induced cytokine synthesis by St. John's wort extracts. Pharmacopsychiatry, 2001; 34 Suppl. 1: 26-28
  67. Detailinformationen: Substanz P und neurogene Entzündung. Fiebich BL, Lieb K: Substanz P und neurogene Entzündung. Immunologie Aktuell, 2001; 1: 148-149
  68. Detailinformationen: Subtle Prefrontal Neuropathology in a Pilot Magnetic Resonance Spectroscopy Study in Patients with Borderline Personality Disorder Tebartz van Elst L, Thiel T, Hesslinger B, Lieb K, Bohus M, Hennig J, Ebert D: Subtle Prefrontal Neuropathology in a Pilot Magnetic Resonance Spectroscopy Study in Patients with Borderline Personality Disorder J Neuropsych Clin N, 2001; 13 (4): 511-514
  69. Detailinformationen: Volumes of the hippocampi and amygdalae in borderline personality disorder Rüsch N, Tebartz van Elst L, Thiel T, Heßlinger B, Lieb K, Bohus M, Ebert D: Volumes of the hippocampi and amygdalae in borderline personality disorder The World Journal of biological Psychiatry, 2001; 2 Suppl. 1: 247S-248S (7th World Congress of Biological Psychiatry), World federation of Societies of Biological Psychiatry (Hrsg)
  70. Detailinformationen: Zum Verständnis von Selbstverletzungen bei Patienten mit Borderline-Persönlichkeitsstörungen Bohus M, Lieb K: Zum Verständnis von Selbstverletzungen bei Patienten mit Borderline-Persönlichkeitsstörungen Zeitschrift für Allgemeinmedizin, 2001; 77: 539-547
  71. Detailinformationen: 25 Fälle Psychatrie (zur Vorbereitung auf mündlcihe Prüfungen mit praxisnahen Fragen und ausführlichen Kommentaren) Lieb K, Heßlinger B, Frauenknecht S: 25 Fälle Psychatrie (zur Vorbereitung auf mündlcihe Prüfungen mit praxisnahen Fragen und ausführlichen Kommentaren), München, Jena: Urban & Fischer, 1. Auflage , 2002.
  72. Detailinformationen: Antagonisten am Substanz P-Rezeptor als neue Klasse von Antidepressiva. Lieb K, Herpfer I, Fiebich BL, Berger M: Antagonisten am Substanz P-Rezeptor als neue Klasse von Antidepressiva. Deut Med Wochenschr, 2002; 127: 2563-2565
  73. Detailinformationen: Effects of the Neuropeptide Substance P on Sleep, Mood, and Neuroendocrine Measures in Healthy Young Men Lieb K, Ahlvers K, Dancker K, Strohbusch S, Reincke M, Feige B, Berger M, Riemann D, Voderholzer U: Effects of the Neuropeptide Substance P on Sleep, Mood, and Neuroendocrine Measures in Healthy Young Men Neuropsychopharmacol, 2002; 27 (6): 1041-1049
  74. Detailinformationen: Increased plasma concentration of maprotiline by coadministration of risperidone Normann C, Lieb K, Walden J: Increased plasma concentration of maprotiline by coadministration of risperidone J Clin Psychopharm, 2002; 22: 92-93
  75. Detailinformationen: Inhibition of LPS-induced p42/44 MAP kinase activation and iNOS/NO synthesis by parthenolide in rat primary microglial cells Fiebich BL, Lieb K, Engels S, Heinrich M: Inhibition of LPS-induced p42/44 MAP kinase activation and iNOS/NO synthesis by parthenolide in rat primary microglial cells J Neuroimmunol, 2002; 132: 18-24
  76. Detailinformationen: Interferon alpha (IFN alpha) and psychiatric syndromes Schaefer M, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Schmidt F, Grunz H, Lieb K: Interferon alpha (IFN alpha) and psychiatric syndromes Prog Neuro-psychoph, 2002; 26: 731-746
  77. Detailinformationen: Neuropeptid-Modulatoren - Psychopharmaka der Zukunft? Herpfer I, Lieb K: Neuropeptid-Modulatoren - Psychopharmaka der Zukunft? Psycho, 2002; 28: 517-521
  78. Detailinformationen: Nonsteroidal drugs and the risk of Alzheimer's disease Hüll M, Lieb K, Fiebich B-L: Nonsteroidal drugs and the risk of Alzheimer's disease New Engl J Med, 2002; 346 (15): 1171-1172
  79. Detailinformationen: Pathways of Inflammatory Activation in Alzheimer's Disease: Potential Targets for Disease Modifying Drugs Hüll M, Lieb K, Fiebich B-L: Pathways of Inflammatory Activation in Alzheimer's Disease: Potential Targets for Disease Modifying Drugs Curr Med Chem, 2002; 9: 83-88
  80. Detailinformationen: Polysomnographic studies in female patients with borderline personality disorder: a comparison with healthy control subjects Philipsen A, Bohus B, Voderholzer U, Riemann D, Lieb K: Polysomnographic studies in female patients with borderline personality disorder: a comparison with healthy control subjects Eur Arch Psy Clin N, 2002; 252 Suppl. 1: 67-67 (8th Congress of the German Society for Biological Psychiatry), Gaebel W, Düsseldorf (Hrsg)
  81. Detailinformationen: Qualitätskriterien für Fortbildung Lieb K, Berner M, Berger M: Qualitätskriterien für Fortbildung Facts&Figures - Intern. Zeitschr. f. Ärztl. Fortbildung, 2002; 22: 22-25
  82. Detailinformationen: Substance P and Affective Disorders: New Treatment Opportunities by Neurokinin 1 Receptor Antagonists? Lieb K, Treffurth Y, Berger M, Fiebich B-L: Substance P and Affective Disorders: New Treatment Opportunities by Neurokinin 1 Receptor Antagonists? Neuropsychobiology, 2002; 45 Suppl. 1: 2-6
  83. Detailinformationen: Substanz P und Substanz-P-Rezeptoranagonisten in der Pathogenese und Therapie affektiver Störungen Lieb K, Herpfer I, Fiebich BL, Berger M: Substanz P und Substanz-P-Rezeptoranagonisten in der Pathogenese und Therapie affektiver Störungen Nervenheilkunde, 2002; 21: 493-496
  84. Detailinformationen: Transient total sleep loss in cerebral Whipple's disease: a longitudinal study Voderholzer U, Riemann D, Gann H, Hornyak M, Juengling F, Schumacher M, Reincke M, von Herbay A, Nishino S, Mignot E, Berger M, Lieb K: Transient total sleep loss in cerebral Whipple's disease: a longitudinal study J Sleep Res, 2002; 11: 321-329
  85. Detailinformationen: Akutbehandlung psychischer Erregungszustände: Was tun Sie, wenn der Patient tobt? Lieb K: Akutbehandlung psychischer Erregungszustände: Was tun Sie, wenn der Patient tobt? MMW Fortschr. Med., 2003; 38: 49-50
  86. Detailinformationen: A voxel-based morphometric MRI study in female patients with borderline personality disorder Rüsch N, Tebartz van Elst L, Ludaescher P, Wilke M, Huppertz HJ, Thiel T, Schmahl C, Bohus M, Lieb K, Heßlinger B, Hennig J, Ebert D: A voxel-based morphometric MRI study in female patients with borderline personality disorder Neuroimage, 2003; 20: 385-392
  87. Detailinformationen: A Voxel-based Morphometric MRI Study in Female Patients with Borderline Personality Disorder Rüsch N, Tebartz van Elst L, Wilke M, Lieb K, Bohus M, Ebert D: A Voxel-based Morphometric MRI Study in Female Patients with Borderline Personality Disorder 2003 (156th Annual Meeting of the American Psychiatric Association, San Francisco)
  88. Detailinformationen: Borderline-Persönlichkeitsstörung - eine polysomnographische Untersuchung im Vergleich zu gesunden Kontrolen Philipsen A, Voderholzer U, Feige B, Bohus M, Lieb K, Riemann D: Borderline-Persönlichkeitsstörung - eine polysomnographische Untersuchung im Vergleich zu gesunden Kontrolen Nervenarzt, 2003 Suppl. 2: 301-301
  89. Detailinformationen: Frontolimbic brain abnormalities in patients with borderline personality disorder. A volumetric magnetic resonance imaging study Tebartz van Elst L, Hesslinger B, Thiel T, Geiger E, Haegele K, Lemieux L, Lieb K, Bohus M, Hennig J, Ebert D: Frontolimbic brain abnormalities in patients with borderline personality disorder. A volumetric magnetic resonance imaging study Biol Psychiat, 2003; 54: 163-171
  90. Detailinformationen: Inhibition of LPS-induced iNOS and NO synthesis in primary rat microglial cells. Lieb K, Engels S, Fiebich BL: Inhibition of LPS-induced iNOS and NO synthesis in primary rat microglial cells. Neurochem Int, 2003; 42: 131-137
  91. Detailinformationen: Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer Friess H, Zhu Z, Liard V, Shi X, Shrikhande SV, Wang L, Lieb K, Korc K, Palma C, Zimmermann A, Reubi JC, Büchler MW: Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer Lab Invest, 2003; 83: 731-742
  92. Detailinformationen: Neurotransmitter changes by interferon-alpha and therapeutic implications. Schaefer M, Schwaiger M, Pich M, Lieb K, Heinz A: Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry, 2003; 36 Suppl. 3: 203-206
  93. Detailinformationen: Off-label-Indikationen in der Psychopharmakotherapie: ein Überblick Normann C, van Calker D, Voderholzer U, Fritze J, Lieb K: Off-label-Indikationen in der Psychopharmakotherapie: ein Überblick Nervenarzt, 2003; 74: 815-825
  94. Detailinformationen: Positron emission tomography in female patients with Borderline personality disorder Juengling FD, Schmahl C, Heßlinger B, Ebert D, Bremner JD, Gostomzyk J, Bohus M, Lieb K: Positron emission tomography in female patients with Borderline personality disorder J Psychiat Res, 2003; 37: 109-115
  95. Detailinformationen: Posttraumatische BelastungsstörungenPsychische Erkrankungen - Klinik und Therapie Frommberger U, Nyberg E, Angenendt J, Lieb K, Berger M: Posttraumatische Belastungsstörungen In: Berger M (Hrsg.): Psychische Erkrankungen - Klinik und Therapie München: Urban & Fischer, 2003; 716.
  96. Detailinformationen: Regloser Patient. Was tun bei stuporösen Zuständen? Lieb K: Regloser Patient. Was tun bei stuporösen Zuständen? MMW Fortschr. Med., 2003; 29: 42-44
  97. Detailinformationen: Substance P and Substance P Receptor Antagonists in the Pathogenesis and Treatment of Affective Disorders Herpfer I, Lieb K: Substance P and Substance P Receptor Antagonists in the Pathogenesis and Treatment of Affective Disorders World J Biol Psychiatry, 2003; 4: 56-63
  98. Detailinformationen: Subtype differentiation of patients with borderline personality disorder using a circumplex model of interpersonal behavior Leihener F, Wagner A, Haaf B, Schmidt C, Lieb K, Stieglitz R, Bohus M: Subtype differentiation of patients with borderline personality disorder using a circumplex model of interpersonal behavior J Nerv Ment Dis, 2003; 191: 248-254
  99. Detailinformationen: Synergistic inhibitory effect of ascorbic acid and acetylsalicylic acid on prostaglandin E2 release in primary rat microglia Fiebich BL, Lieb K, Kammerer N, Hüll M: Synergistic inhibitory effect of ascorbic acid and acetylsalicylic acid on prostaglandin E2 release in primary rat microglia J Neurochem, 2003; 86 (1): 173-178
  100. Detailinformationen: Valproic acid inhibits substance P-induced activation of protein kinase C epsilon and expression of the substance P-receptor Lieb K, Treffurth Y, Hamke M, Shankar Akundi R, von Kleinsorgen M, Fiebich BL: Valproic acid inhibits substance P-induced activation of protein kinase C epsilon and expression of the substance P-receptor J Neurochem, 2003; 86 (1): 69-76
  101. Detailinformationen: 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline induced apoptosis in the human neuroblastoma cell line SK-N-SH Akundi RS, Macho A, Munoz E, Lieb K, Bringmann G, Clement HW, Hüll M, Fiebich BL: 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline induced apoptosis in the human neuroblastoma cell line SK-N-SH J Neurochem, 2004; 91 (2): 263-273
  102. Detailinformationen: Akute Suizidalität [Fortbildung Notfallseminar] Lieb K: Akute Suizidalität [Fortbildung Notfallseminar] MMW Fortschr Med, 2004; 146: 294-295
  103. Detailinformationen: Antiinflammatory effects of 5-HT3 receptor antagonists in lipopolysaccharide-stimulated primary human monocytes Fiebich BL, Akundi RS, Lieb K, Candelario-Jalil E, Gmeiner D, Haus U, Muller W, Stratz T, Munoz E: Antiinflammatory effects of 5-HT3 receptor antagonists in lipopolysaccharide-stimulated primary human monocytes Scand J Rheumatol, 2004; 119 Suppl. Suppl.: 28-32
  104. Detailinformationen: Borderline personality disorder Lieb K, Zanarini M, Schmahl C, Linehan M, Bohus M: Borderline personality disorder Lancet, 2004; 364: 453-461
  105. Detailinformationen: Borderline Persönlichkeitsstörung. Kasuistik: Ein schmaler Grat. Peters J, Lieb K: Borderline Persönlichkeitsstörung. Kasuistik: Ein schmaler Grat. Via medici, 2004; 1: 50-53
  106. Detailinformationen: Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder Philipsen A, Richter H, Schmahl C, Petrs J, Rüsch N, Bohus M, Lieb K: Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder J Clin Psychiat, 2004; 65 (10): 1414-1419
  107. Detailinformationen: Cognitive impairment in patients with chronic hepatitis treated with interferon alpha. Results from a prospective study Lieb K, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Janssen G, Schäfer M: Cognitive impairment in patients with chronic hepatitis treated with interferon alpha. Results from a prospective study Eur Psychiat, 2004 (in Druck)
  108. Detailinformationen: Differential nociceptive deficits in patients with borderline personality disorder and self-injurious behavior: Laser-evoked potentials, spatial discrimination of noxious stimuli, and pain ratings Schmahl C, Greffrath W, Baumgärtner U, Schlereth T, Magerl W, Philipsen A, Lieb K, Bohus M, Treede RD: Differential nociceptive deficits in patients with borderline personality disorder and self-injurious behavior: Laser-evoked potentials, spatial discrimination of noxious stimuli, and pain ratings Pain, 2004; 110 (1-2): 470-479
  109. Detailinformationen: Effectiveness of inpatient dialectical behavioral therapy for borderline personality disorder - a controlled trial Bohus M, Haaf B, Simms T, Schmahl C, Unckel C, Lieb K, Linehan M: Effectiveness of inpatient dialectical behavioral therapy for borderline personality disorder - a controlled trial Behav Res Ther, 2004; 42: 487-499
  110. Detailinformationen: Intensivkurs Psychiatrie und Psychotherapie Brunnhuber S, Frauenknecht S, Lieb K: Intensivkurs Psychiatrie und Psychotherapie, München: Urban und Fischer, 5. Auflage , 2004.
  111. Detailinformationen: Management der akuten Suizidalität Lieb K: Management der akuten Suizidalität MMW Fortschr Med, 2004; 146 (16): 51-52
  112. Detailinformationen: Naloxone in the Treatment of Acute Dissociative States in Female Patients with Borderline Personality Disorder Philipsen A, Schmahl C, Lieb K: Naloxone in the Treatment of Acute Dissociative States in Female Patients with Borderline Personality Disorder Pharmacopsychiatry, 2004; 37: 196-199
  113. Detailinformationen: ncreased diurnal salivary cortisol in women with Borderline personality disorder Lieb K, Rexhausen JE, Kahl KG, Schweiger U, Philipsen A, Hellhammer DH, Bohus M: ncreased diurnal salivary cortisol in women with Borderline personality disorder J Psychiat Res, 2004; 38: 559-565
  114. Detailinformationen: Neurokinine in der Depressionstherapie Lieb K: Neurokinine in der Depressionstherapie Neurotransmitter, 2004; 15: 58-60
  115. Detailinformationen: New developments in the neurobiology of borderline personality disorder Bohus M, Schmahl C, Lieb k: New developments in the neurobiology of borderline personality disorder Curr Psychiatry Rep, 2004; 6: 43-50
  116. Detailinformationen: Serum levels of substance P and response to antidepressant pharmacotherapy Lieb K, Walden J, Grunze H, Fiebich BL, Berger M, Normann C: Serum levels of substance P and response to antidepressant pharmacotherapy Pharmacopsychiatry, 2004; 37: 238-239
  117. Detailinformationen: Welche Rolle spielt Substanz P für die Entwicklung neuer Antidepressiva? Lieb K: Welche Rolle spielt Substanz P für die Entwicklung neuer Antidepressiva? Neurotransmitter, 2004 (in Druck)
  118. Detailinformationen: Affective dysregulation and dissociative experience in female patients with borderline personality disorder: a startle response study Ebner-Priemer UW, Badeck S, Beckmann C, Wagner A, Feige B, Weiss I, Lieb K, Bohus M: Affective dysregulation and dissociative experience in female patients with borderline personality disorder: a startle response study J Psychiat Res, 2005; 39 (1): 85-92
  119. Detailinformationen: Deep brain stimulation for treatment of refractory depression Schläpfer TE, Lieb K: Deep brain stimulation for treatment of refractory depression Lancet, 2005; 366: 1420-1422
  120. Detailinformationen: Dialektisch-behaviorale Therapie in der stationären Alkoholentwöhnung Mayer-Bruns F, Lieb K, Dannegger E, Jacob G: Dialektisch-behaviorale Therapie in der stationären Alkoholentwöhnung Nervenarzt, 2005; 76: 339-343
  121. Detailinformationen: Effects of substance P and its antagonist L-733060 on long term potentiation in guinea pig hippocampal slices. Langosch JM, Kupferschmid S, Heinen M, Walden J, Herpfer I, Fiebich BL, Lieb K: Effects of substance P and its antagonist L-733060 on long term potentiation in guinea pig hippocampal slices. Prog Neuro-psychoph, 2005; 29 (2): 315-319
  122. Detailinformationen: Increased delta-power and discrepancies in objective and subjective sleep measurements in borderline personality disorder Philipsen A, Feige B, Al-Shajlawi A, Schmahl C, Bohus M, Richter H, Voderholzer U, Lieb K, Riemann D: Increased delta-power and discrepancies in objective and subjective sleep measurements in borderline personality disorder J Psychiat Res, 2005; 39 (5): 489-498
  123. Detailinformationen: Intensivkurs Psychiatrie und Psychotherapie Brunnhuber S, Frauenknecht S, Lieb K: Intensivkurs Psychiatrie und Psychotherapie, München: Elsevier Urban& Fischer, 5. Auflage. Auflage , 2005.
  124. Detailinformationen: No modulatory effect of neurokinin-1 receptor antagonists on serotonin-uptake in human and rat brain synaptosomes Lieb K, Fiebich BL, Herpfer I, Mantovani M, Löffler M, Feuerstein T: No modulatory effect of neurokinin-1 receptor antagonists on serotonin-uptake in human and rat brain synaptosomes Eur Neuropsychopharm, 2005; 15 (6): 641-646
  125. Detailinformationen: Serotonin via 5-HT receptors activates p38 mitogen-activated protein kinase and protein kinase C epsilon resulting in interleukin-6 synthesis in human U373 MG astrocytoma cells Lieb K, Biersack L, Waschbisch A, Orlikowski S, Akundi RS, Candelario-Jalil, Hüll M, Fiebich B: Serotonin via 5-HT receptors activates p38 mitogen-activated protein kinase and protein kinase C epsilon resulting in interleukin-6 synthesis in human U373 MG astrocytoma cells J Neurochem, 2005; 93 (3): 549-559
  126. Detailinformationen: Signal transduction pathways regulating cyclooxygenase-2 in lipopolysaccharide-activated primary rat microglia Akundi RS, Candelario-Jalil E, Hess S, Hüll M, Lieb K, Gebicke-Haerter PJ, Fiebich BL: Signal transduction pathways regulating cyclooxygenase-2 in lipopolysaccharide-activated primary rat microglia Glia, 2005; 51 (3): 199-208
  127. Detailinformationen: Sleep in adults with attention deficit/ hyperactivity disorder: a controlled polysomnographic study including spectral analysis of the sleep EEG Philipsen A, Feige B, Hesslinger B, Ebert D, Carl C, Hornyak M, Lieb K, Voderholuzer U, Riemann D: Sleep in adults with attention deficit/ hyperactivity disorder: a controlled polysomnographic study including spectral analysis of the sleep EEG Sleep, 2005; 28 (8): 877-884
  128. Detailinformationen: Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential Herpfer I, Lieb K: Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential Cns Drugs, 2005; 19 (4): 275-293
  129. Detailinformationen: The 5-HT3 receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway De la Vega M, Munoz E, Calzado MA, Lieb K, Candelario-Jalil E, Gescheidmeir H, Farber L, Müller W, Stratz T, Fiebich BL: The 5-HT3 receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway Biochem Pharmacol, 2005; 70 (3): 369-380
  130. Detailinformationen: Zur pathophysiologischen Bedeutung der Amygdala in der Affektregulation bei psychischen Störungen Van Elst LT, Lieb K: Zur pathophysiologischen Bedeutung der Amygdala in der Affektregulation bei psychischen Störungen Nervenheilkunde, 2005; 24: 89-98
  131. Detailinformationen: 50 Fälle Psychiatrie und Psychotherapie Lieb K, Hesslinger B, Jacob GA: 50 Fälle Psychiatrie und PsychotherapieUrban und Fischer, 2. Auflage. Auflage , 2006.
  132. Detailinformationen: Ascorbic acid enhances the inhibitory effect of aspirin on neuronal cyclooxygenase-2-mediated prostaglandin E (2) production Candelario-Jalil E, Akundi RS, Bhatia HS, Lieb K, Appel K, Munoz E, Hüll M, Fiebich BL: Ascorbic acid enhances the inhibitory effect of aspirin on neuronal cyclooxygenase-2-mediated prostaglandin E (2) production J Neuroimmunol, 2006; 174: 39-51
  133. Detailinformationen: Borderline-Persönlichkeitsstörung Jacob GA, Lieb K: Borderline-Persönlichkeitsstörung Psychiatrie und Psychotherapie up2date, 2006 (in Druck)
  134. Detailinformationen: Cognitive impairment in patients with chronic hepatitis treated with interferon alpha Lieb K, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Janssen G, Schäfer M: Cognitive impairment in patients with chronic hepatitis treated with interferon alpha Eur Psychiat, 2006; 21: 204-210
  135. Detailinformationen: Deep-brain stimulation for Parkinson´s disease Lieb K, Schlaepfer TE: Deep-brain stimulation for Parkinson´s disease New Engl J Med, 2006; 355 (21): 2256-2256
  136. Detailinformationen: Gruppentherapiemodul zur Stärkung des Selbstwertes bei PatientInnen mit Borderline-Persönlichkeitsstörung Jacob GA, Richter H, Lammers CH, Bohus M, Lieb K: Gruppentherapiemodul zur Stärkung des Selbstwertes bei PatientInnen mit Borderline-Persönlichkeitsstörung Verhaltenstherapie, 2006 (in Druck)
  137. Detailinformationen: Increased nocturnal Interleukin-6 (IL-6) excretion in patients with primary insomnia: a pilot study Burgos I, Richter L, Fiebich B, Lieb K, Voderholzer U, Riemann D: Increased nocturnal Interleukin-6 (IL-6) excretion in patients with primary insomnia: a pilot study Brain Behav Immun, 2006; 20 (3): 246-253
  138. Detailinformationen: Neural correlates of antinociception in borderline personality disorder Schmahl C, Bohus M, Esposito F, Treede RD, Di Salle F, Greffrath W, Ludäscher P, Jochims A, Lieb K, Scheffler K, Hennig J, Seifritz E: Neural correlates of antinociception in borderline personality disorder Arch Gen Psychiat, 2006; 63: 659-667
  139. Detailinformationen: Nocturnal serum leptin values in chronic primary insomnia: a preliminary report Riemann D, Burgos I, Richter L, Klein T, Fiebich B, Feige B, Freyer T, Lieb K, Voderholzer U: Nocturnal serum leptin values in chronic primary insomnia: a preliminary report Somnologie, 2006; 10: 192-199
  140. Detailinformationen: No response of plasma substance P, but delayed increase of interleukin-1 receptor antagonist to acute psychosocial stress Rohleder N, Wolf JM, Herpfer I, Fiebich BL, Kirschbaum C, Lieb K: No response of plasma substance P, but delayed increase of interleukin-1 receptor antagonist to acute psychosocial stress Life Sci, 2006; 78: 3082-3089
  141. Detailinformationen: Self-stigma, empowerment, and perceived legitimacy of discrimination among women with mental illness Rüsch N, Lieb K, Bohus M, Corrigan PW: Self-stigma, empowerment, and perceived legitimacy of discrimination among women with mental illness Psychiat Serv, 2006; 57: 399-402
  142. Detailinformationen: Self-stigma in women with borderline personality disorder and women with social phobia Rüsch N, Hölzer A, Hermann C, Schramm E, Jacob GA, Bohus M, Lieb K, Corrigan PW: Self-stigma in women with borderline personality disorder and women with social phobia J Nerv Ment Dis, 2006; 194: 766-773
  143. Detailinformationen: Signaltransduktion der Substanz P vermittelten Geninduktion von IL-6Lehrbuch der klinischen Pathophysiologie komplexer chronischer Erkrankungen Fiebich BL, Herpfer I, Lieb K: Signaltransduktion der Substanz P vermittelten Geninduktion von IL-6 In: Straub R (Hrsg.): Lehrbuch der klinischen Pathophysiologie komplexer chronischer Erkrankungen Göttingen: Vandenhoeck & Rupprecht, 2006; 57-59.
  144. Detailinformationen: Substance P induces expression of the corticotropin releasing factor I by activation of the neurokinin-1 receptor Hamke M, Herpfer I, Lieb K, Wandelt C, Fiebich BL: Substance P induces expression of the corticotropin releasing factor I by activation of the neurokinin-1 receptor Brain Res, 2006; 1102: 135-144
  145. Detailinformationen: Tiefenhirnstimulation bei psychiatrischen ErkrankungenHighlights in Psychiatrie und Psychotherapie 2005 - 2006 Voderholzer U, Schläpfer T, Lieb K: Tiefenhirnstimulation bei psychiatrischen Erkrankungen In: Berger M, Normann C (Hrsg.): Highlights in Psychiatrie und Psychotherapie 2005 - 2006 München: Elsevier Urban & Fischer, 2006; 52-62.
  146. Detailinformationen: Universitäre Privatisierung als Chance oder Alptraum? Aldenhoff J, Fritze J, Lieb K: Universitäre Privatisierung als Chance oder Alptraum? Nervenarzt, 2006; 77: 1393-1398
  147. Detailinformationen: Wem gehört die Psychotherapie? Lieb K, Berger M: Wem gehört die Psychotherapie? Psychodynamische Psychotherapie, 2006; 5: 147-153
  148. Detailinformationen: An intensive treatment program of interpersonal psychotherapy plus pharmacotherapy for depressed inpatients: acute and long-term results Schramm E, van Calker D, Dykierek P, Lieb K, Kech S, Zobel I, Leonhart R, Berger M: An intensive treatment program of interpersonal psychotherapy plus pharmacotherapy for depressed inpatients: acute and long-term results Am J Psychiat, 2007; 164: 768-777
  149. Detailinformationen: Borderline-Persönlichkeitsstörung Jacob G, Lieb K: Borderline-Persönlichkeitsstörung Psychiatrie und Psychotherapie up2date, 2007; 1: 1-18
  150. Detailinformationen: Corpus callosum abnormalities in women with borderline personality disorder and co-morbid attention deficit hyperactivity disorder Rüsch, N, Luders, E, Lieb, K, Zahn, R, Ebert, D, Thompson, PM, Toga, AW, Tebarzt van Elst, L: Corpus callosum abnormalities in women with borderline personality disorder and co-morbid attention deficit hyperactivity disorder J Psychiatr Neurosci, 2007; 32: 417-422
  151. Detailinformationen: Effects of substance P on memory and mood in healthy male subjects Herpfer I, Katzev M, Feige B, Fiebich BL, Voderholzer U, Lieb K: Effects of substance P on memory and mood in healthy male subjects Hum Psychopharm Clin, 2007; 22: 567-573
  152. Detailinformationen: Elevated pain thresholds correlate with dissociation and aversive arousal in patients with borderline personality disorder Ludäscher P, Bohus M, Lieb K, Philipsen A, Jochims C, Schmahl C: Elevated pain thresholds correlate with dissociation and aversive arousal in patients with borderline personality disorder Psychiat Res, 2007; 149: 291-296
  153. Detailinformationen: Evidence of disturbed amygdalar energy metabolism in patients with borderline personality disorder Van Elst LT, Ludäscher P, Thiel T, Büchert M, Hesslinger B, Bohus M, Rüsch N, Hennig J, Ebert D, Lieb K: Evidence of disturbed amygdalar energy metabolism in patients with borderline personality disorder Neurosci Lett, 2007; 417: 36-41
  154. Detailinformationen: Inferior frontal white matter microstructure and patterns of psychopathology in women with borderline personality disorder and comorbid attention deficit hyperactivity disorder Rüsch N, Weber K, Il´yasov K, Lieb K, Ebert D, Hennig J, van Elst TL: Inferior frontal white matter microstructure and patterns of psychopathology in women with borderline personality disorder and comorbid attention deficit hyperactivity disorder Neuroimage, 2007; 35: 738-747
  155. Detailinformationen: Measuring shame and guilt by self-report questionnaires: a validation study Rüsch N, Corrigan PW, Bohus M, Jacob GA, Lieb K: Measuring shame and guilt by self-report questionnaires: a validation study Psychiat Res, 2007; 150: 313-325
  156. Detailinformationen: On determining sensitivity to pain in borderline personality disorder - reply Schmahl C, Bohus M, Esposito F, Treede RD, DiSalle F, Greffrath W, Ludäscher P, Jochims A, Lieb K, Scheffler K, Hennig J, Seifritz E: On determining sensitivity to pain in borderline personality disorder - reply Arch Gen Psychiat, 2007; 64: 748-749
  157. Detailinformationen: Schemnatherapie bei schweren Persönlichkeitsstörungen Jacob, G, Dieckmann, E, Lieb, K: Schemnatherapie bei schweren Persönlichkeitsstörungen INFO Neurologie & Psychiatrie, 2007; 9: 46-53
  158. Detailinformationen: Shame and implicit self-concept in women with borderline personality disorder Rüsch N, Lieb K, Göttler I, Herrmann C, Schramm E, Richter H, Jacob GA, Corrigan PW, Bohus M: Shame and implicit self-concept in women with borderline personality disorder Am J Psychiat, 2007; 164: 500-508
  159. Detailinformationen: State affective instability in borderline personality disorder assessed by ambulatory monitoring Ebner-Priemer, UW, Kuo, J, Kleindienst, N, Welch, SS, Reisch, T, Reinhard, I, Lieb, K, Linehan, MM, Bohus, M: State affective instability in borderline personality disorder assessed by ambulatory monitoring Psychol Med, 2007; 37: 961-970
  160. Detailinformationen: The impact of posttraumatic stress disorder on dysfunctional implicit and explicit emotions among women with borderline personality disorder Rüsch N, Corrigan PW, Bohus M, Kühlert T, Jacob GA, Lieb K: The impact of posttraumatic stress disorder on dysfunctional implicit and explicit emotions among women with borderline personality disorder J Nerv Ment Dis, 2007; 195: 537-539
  161. Detailinformationen: Verhaltenstherapie zur Steigerung des Selbstwertes bei Patienten mit Persönlichkeitsstörungen Jacob,G, Lieb, K: Verhaltenstherapie zur Steigerung des Selbstwertes bei Patienten mit Persönlichkeitsstörungen Persönlichkeitsstörungen, 2007; 11: 59-65
  162. Detailinformationen: Verkürzung der Übermittlungszeit von Arztbriefen stationär behandelter Patienten in der Psychiatrie und Psychotherapie Lieb K, Trieschmann S, Buhl C, Vielhaber K, Mehraein S, Härter M: Verkürzung der Übermittlungszeit von Arztbriefen stationär behandelter Patienten in der Psychiatrie und Psychotherapie Nervenarzt, 2007; 78: 322-327
  163. Detailinformationen: Attention deficit/hyperactivity disorder as a potentially aggravating factor in borderline personality disorders Philipsen, A, Limberger, K, Lieb, K, Feige, B, Kleindienst, N, Ebner-Priemer, U, Barth, J, Schmahl,C, Bohus, M: Attention deficit/hyperactivity disorder as a potentially aggravating factor in borderline personality disorders Brit J Psychiat, 2008; 192: 118-123
  164. Detailinformationen: Neurochemical alterations in women with borderline personality disorder and co-morbid attention-deficit hyperactivity disorder. Rüsch, N, Boeker, M, Büchert, M, Glauche V, Bohrmann C, Ebert D, Lieb K, Hennig J, van Elst LT: Neurochemical alterations in women with borderline personality disorder and co-morbid attention-deficit hyperactivity disorder. World J Biol Psychia, 2008: 1-10: http://dx.doi.org/10.1080/15622970801958331 (in Druck)
  165. Detailinformationen: Pharmakotherapie der Borderline-Persönlickeitsstörung. Evidenzbasierte Empfehlungen für den klinischen Alltag Stoffers, J, Lieb, K: Pharmakotherapie der Borderline-Persönlickeitsstörung. Evidenzbasierte Empfehlungen für den klinischen Alltag Info Neurologie & Psychiatrie, 2008; 10: 30-35
  166. Detailinformationen: Predictors of dropout from inpatient dialectical behavior therapy among women with borderline personality disorder Rüsch, N, Schiel, S, Corrigan, PW, Leihener, F, Jacob, GA, Olschewski, M, Lieb, K, Bohus, M: Predictors of dropout from inpatient dialectical behavior therapy among women with borderline personality disorder J Behav Ther Exp Psy, 2008; 39: 497-503
  167. Detailinformationen: Regulation of prostaglandin E (2) synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2 De Oliveira, AC, Candelario-Jalil, E, Bhatia, HS, Lieb, K, Hüll, M, Fiebich, BL: Regulation of prostaglandin E (2) synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2 Glia, 2008; 56: 844-855
  168. Detailinformationen: Time courses of anger and other emotions in women with borderline personality disorder: a preliminary study Jacob, GA, Günzler, C, Zimmermann, S, Scheel, CN, Rüsch, N, Leonhart, R, Nerb, J, Lieb, K: Time courses of anger and other emotions in women with borderline personality disorder: a preliminary study J Behav Ther Exp Psy, 2008; 39: 391-402
  169. Detailinformationen: Current status of inpatient treatment for borderline personality disorders in Germany Jacob, G, Allemann, R, Schornstein, K, Lieb, K: Current status of inpatient treatment for borderline personality disorders in Germany Psychiat Prax, 2009; 36: 387-389
  170. Detailinformationen: Emotional reactions to standardized stimuli in women with borderline personality disorder Jacob, GA, Hellstern, K, Ower, N, Pillmann, M, Scheel, C, Rüsch, N, Lieb, K: Emotional reactions to standardized stimuli in women with borderline personality disorder J Nerv Ment Dis, 2009; 197: 808-815
  171. Detailinformationen: Extraction of prefronto-amygdalar pathways by combining probability maps Bracht T, Tuscher O, Schnell S, Kreher B, Rüsch N, Glauche V, Lieb K, Ebert D, Il´yasov KA, Hennig C, Weiller C, van Elst LT, Saur D: Extraction of prefronto-amygdalar pathways by combining probability maps Psychiat Res, 2009; 174: 217-222: http://dx.doi.org/10.1016/j.pscychresns.2009.05.001
  172. Detailinformationen: Posttraumatische BelastungsstörungenPsychische Erkrankungen Frommberger, U, Nyberg, E, Angenendt, J, Lieb, K, Berger, M: Posttraumatische Belastungsstörungen In: Berger, M unter Mitarbeit von Hecht, H (Hrsg.): Psychische Erkrankungen , 3.. Auflage. München, Jena: Elsevier/ Urban & Fischer, 2009; 667-696.
  173. Detailinformationen: Schematherapie mit dem Moduskonzept bei Persönlichkeitsstörungen Jacob, GA, Bernstein, D, Lieb, K, Arntz, A: Schematherapie mit dem Moduskonzept bei Persönlichkeitsstörungen Psychiatrie und Psychotherapie up2date, 2009; 3: 105-119
  174. Detailinformationen: Schwierige Gesprächssituationen in Psychiatrie und Psychotherapie Jacob, GA, Lieb, K, Berger, M (Hrsg.): Schwierige Gesprächssituationen in Psychiatrie und Psychotherapie, München: Elsevier, 2009.
  175. Detailinformationen: Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy van Calker, D, Zobel, I, Dykierek, P, Deimel, CM,, Kech, S, Lieb, K, Berger, M, Schramm, E: Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy J Affect Disorders, 2009; 114: 243-253
  176. Detailinformationen: Verhaltenstherapie zur Steigerung des Selbstwertes bei Patienten mit Persönlichkeitsstörungen Jacob GA, Lieb K: Verhaltenstherapie zur Steigerung des Selbstwertes bei Patienten mit Persönlichkeitsstörungen Persönlichkeitsstörungen Theorie und Therapie, 2009 (in Druck)
  177. Detailinformationen: Group therapy module to enhance self-esteem in patients with borderline personality disorder: a pilot study Jacob, GA, Gabriel, S, Roepke, S, Stoffers, J, Lieb, K, Lammers, CH: Group therapy module to enhance self-esteem in patients with borderline personality disorder: a pilot study Int J Group Psychoth, 2010; 60: 373-387
  178. Detailinformationen: Neurochemical alterations in women with borderline personality disorder comorbid with attention-deficit hyperactivity disorder Rüsch, N, Boeker, M, Büchert, M, Glauche, V, Bohrmann, C, Ebert, D, Lieb, K, hennig, J, van Elst, LT: Neurochemical alterations in women with borderline personality disorder comorbid with attention-deficit hyperactivity disorder World J Biol Psychia, 2010 (in Druck)
  179. Detailinformationen: Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with teratment as usual (TAU) in patients with major depressive disorder - the EMC trial Tadic, A, Gorbulev, S, dahmen, N, Hiemke, C, Braus, DF, Röschke, J, van Calker, D, Wachtlin, D, Kronfeld, K, Gorbauch, T, Seibert-Grafe, M, Lieb, K, the EMC study group: Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with teratment as usual (TAU) in patients with major depressive disorder - the EMC trial Trials, 2010; 26: 21-21
  180. Detailinformationen: Reduced interhemispheric structural connectivity between anterior cingulate cortices in borderline personality disorder Rüsch, N, Bracht, T, Kreher, BW, Schnell, S, Glauche, V, Il´yasov, KA, Ebert, D, Lieb, K, Hennig, J, Saur, D, van Elst, LT: Reduced interhemispheric structural connectivity between anterior cingulate cortices in borderline personality disorder Psychiat Res, 2010; 181: 151-154

    Institut für Psychologie, Abteilung für Klinische Psychologie und Psychotherapie

  1. Detailinformationen: Sleep in Adults with Attention Deficit Hyperactivity Disorder (ADHD): A Controlled Polysomnographic Study including Spectral Analysis of the sleep EEG Philipsen, A., Feige, B., Hesslinger, B., Ebert, E., Carl, C., Hornyak, M., Lieb, K., Voderholzer, U., & Riemann, D.: Sleep in Adults with Attention Deficit Hyperactivity Disorder (ADHD): A Controlled Polysomnographic Study including Spectral Analysis of the sleep EEG Sleep, 2005; 28: 877-884

    SFB 364 "Molekulare und zelluläre Grundlagen der Tumortherapie",

  1. Detailinformationen: IL-1 and TNF , but not IL-6, induce 1-antichymotrypsin expression in the human astrocytoma cell line U373 MG. Machein U., Lieb K., Huell M. and Fiebich B.L.: IL-1 and TNF , but not IL-6, induce 1-antichymotrypsin expression in the human astrocytoma cell line U373 MG. Neuroreport, 1995; 6: 2283-2286
  2. Detailinformationen: Stimulation of the sphingomyelin pathway induces IL-6 gene expression in human astrocytoma cells. Fiebich B.L., Lieb K., Berger M., and Bauer J.: Stimulation of the sphingomyelin pathway induces IL-6 gene expression in human astrocytoma cells. J. Neuroimmunol., 1995; 63: 207-211
  3. Detailinformationen: The Neuropeptide Substance P Activates Transcription Factor NF-kB and kB-Dependent Gene Expression in Human Astrocytoma Cells. Lieb K, Fiebich B L, Berger M, Bauer J, Schulze-Osthoff K: The Neuropeptide Substance P Activates Transcription Factor NF-kB and kB-Dependent Gene Expression in Human Astrocytoma Cells. The Journal of Immunology, 1997; 159: 4952-4958

    Zentrum für Geriatrie und Gerontologie Freiburg, der Albert-Ludwigs-Universität

  1. Detailinformationen: Demenzerkrankungen Diagnose, Differentialdiagnose und Therapie. Rösler M., Lieb K., Wolf R., Berger M., Bauer J.: Demenzerkrankungen Diagnose, Differentialdiagnose und Therapie. Fortschritte der Medizin, 1996
  2. Detailinformationen: Demenzerkrankungen - Diagnosen - Differentialdiagnose und Therapie. Rösler M, Hüll M, Lieb K, Wolf R, Berger M, Bauer J: Demenzerkrankungen - Diagnosen - Differentialdiagnose und Therapie. Fortschr Med, 1997; 114 (in Druck)

    Medizinische Universitätsklinik, Abteilung Rheumatologie und Klinische Immunologie

  1. Detailinformationen: Immunologische Systemerkrankungen als Differentialdiagnose in der Psychiatrie. Lieb K, Vaith P, Berger M, Bauer J: Immunologische Systemerkrankungen als Differentialdiagnose in der Psychiatrie. Nervenarzt, 1997; 68: 696-707

    Neurologische Universitätsklinik und Poliklinik, Abteilung Neurologie und Neurophysiologie

  1. Detailinformationen: Impairment in preattentive visual processing in patients with Parkinson´s disease. Lieb K, Brucker S, Bach M, Els T, Lücking CH, Greenlee MW: Impairment in preattentive visual processing in patients with Parkinson´s disease. Brain, 1999; 122: 303-313
  2. Detailinformationen: Pain perception during self-reported distress and calmness in patients with borderline personality disorder and self-mutilating behavior Bohus M, Limberger M, Ebner U, Glocker FX, Schwarz B, Wernz M, Lieb K: Pain perception during self-reported distress and calmness in patients with borderline personality disorder and self-mutilating behavior Psychiat Res, 2000; 95: 251-260
  3. Detailinformationen: Effects of substance P on memory and mood in healthy male subjects. Herpfer I, Katzev M, Feige B, Fiebich BL, Voderholzer U, Lieb K: Effects of substance P on memory and mood in healthy male subjects. Hum Psychopharmacol, 2007; 22 (8): 567-573
  4. Detailinformationen: Extraction of prefronto-amygdalar pathways by combining probability maps. Bracht T, Tuscher O, Schnell S, Kreher B, Rusch N, Glauche V, Lieb K, Ebert D, Il'yasov KA, Hennig J, Weiller C, van Elst LT, Saur D: Extraction of prefronto-amygdalar pathways by combining probability maps. Psychiat Res, 2009; 174 (3): 217-222: http://dx.doi.org/10.1016/j.pscychresns.2009.05.001

    Radiologisches Zentrum, Nuklearmedizinische Klinik

  1. Detailinformationen: Interferon-alpha/beta induced changes in cerebral glucose metabolism as measured by positron emission tomography. Lieb K., Jüngling FD., Brandt C., Lücking CH., Berger M., Bauer J.: Interferon-alpha/beta induced changes in cerebral glucose metabolism as measured by positron emission tomography. Eur Arch Psych Clin Neurosci, 1998; 248: 135
  2. Detailinformationen: Cortical Dysfunction in Patients treated with low-dosage IFN-alpha Juengling FD, Gut O, Engelbrecht MA, Blum HE, Bauer J, Moser E, Nitzsche EU, Lieb K: Cortical Dysfunction in Patients treated with low-dosage IFN-alpha NeuroImage, 1999: 570
  3. Detailinformationen: FDG-PET zum Nachweis IFN-Alpha assoziierter zerebraler Glukose-stoffwechselstörungen Juengling FD, Lieb K, Gut O, Bauer J, Moser E, Nitzsche EU: FDG-PET zum Nachweis IFN-Alpha assoziierter zerebraler Glukose-stoffwechselstörungen Nuklearmedizin, 1999; 2: A21
  4. Detailinformationen: Prefrontal cortical hypometabolism during low-dose Interferon alpha treatment Juengling FD, Ebert D, Gut O, Engelbrecht MA, Rasenack J, Nitzsche EU, Bauer J, Lieb K: Prefrontal cortical hypometabolism during low-dose Interferon alpha treatment Psychopharmacology, 2000; 152 (4): 383-389

    Institut für Medizinische Mikrobiologie und Hygiene, Abteilung Virologie

  1. Detailinformationen: Depression, Borna disease, and amantadine. Lieb K, Hufert FT, Bechter K, Bauer J, Kornhuber J: Depression, Borna disease, and amantadine. Lancet, 1997; 349: 958
  2. Detailinformationen: No Borna disease virus-specific RNA detected in blood from psychiatric patients in different regions of Germany. Lieb K., Hallensleben W., Czygan M., Atitz L., Staeheli P.: No Borna disease virus-specific RNA detected in blood from psychiatric patients in different regions of Germany. The Lancet, 1997; 350: 1002
  3. Detailinformationen: Borna Disease Virus und psychiatrische Erkrankungen. Lieb K., Czygan M., Sauder C., Hallensleben W., Staeheli P.: Borna Disease Virus und psychiatrische Erkrankungen. Deut Med Wochenschr, 1998; 123: 1217-1218
  4. Detailinformationen: Bornaviren und psychiatrische Erkrankungen: Zusammenhänge weiterhin unklar Stäheli P., Lieb K.: Bornaviren und psychiatrische Erkrankungen: Zusammenhänge weiterhin unklar IKMI, 1998; 3: 2
  5. Detailinformationen: Bornaviren - Ursache psychiatrischer Erkrankungen? Lieb K., Staeheli P.: Bornaviren - Ursache psychiatrischer Erkrankungen? Ars Medici, 1998; 17: 1077-1079
  6. Detailinformationen: Borna disease virusin human brains with a rare form of hippocampal degeneration but not in brains of patients with common neuropsychiatric disorders. Czygan M., Hallensleben W., Hofer M., Pollk S., Sauder C., Bilzer T., Blümcke I., Riederer P., Bogert B., Falkai P., Schwarz M.J., Masliah E., Staeheli P., Hufert F.T., Lieb K.: Borna disease virusin human brains with a rare form of hippocampal degeneration but not in brains of patients with common neuropsychiatric disorders. J Infect Dis, 1999; 180: 1695-1699
  7. Detailinformationen: Demonstration of Borna Disease Virus Nucleic Acid in a Patient with chronic fatigue syndrome. Reply to the Editor. Staeheli P., Lieb K., Czygan M., Sauder C., Schwemmle M.: Demonstration of Borna Disease Virus Nucleic Acid in a Patient with chronic fatigue syndrome. Reply to the Editor. J Infect Dis, 2000; 181: 1861-1862
  8. Detailinformationen: Borna disease virus - does it infect humans and cause psychiatric disorders? Lieb K, Staeheli P.: Borna disease virus - does it infect humans and cause psychiatric disorders? J Clin Virol, 2001; 21: 119-127
  9. Detailinformationen: Bornavirus and psychiatric disorders - fact or fiction? Staeheli P, Lieb K.: Bornavirus and psychiatric disorders - fact or fiction? J Med Microbiol, 2001; 50: 579-581

    Augenklinik, Abteilung Neuroophthalmologie und Schielbehandlung

  1. Detailinformationen: Impairment in preattentive visual processing in patients with Parkinson's disease Lieb K, Brucker S, Bach M, Els T, Lücking CH, Greenlee MW: Impairment in preattentive visual processing in patients with Parkinson's disease Brain, 1999; 122: 303-313

    Medizinische Universitätsklinik, Abteilung Innere Medizin II

  1. Detailinformationen: Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Juengling FD, Ebert D, Gut O, Engelbrecht MA, Rasenack J, Nitzsche EU, Bauer J, Lieb K: Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology, 2000; 152 (4): 383-389
  2. Detailinformationen: Sleep deprivation and growth-hormone secretion. Lieb K, Reincke M, Riemann D, Voderholzer U: Sleep deprivation and growth-hormone secretion. Lancet, 2000; 356 (9247): 2096-2097
  3. Detailinformationen: Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Lieb K, Ahlvers K, Dancker K, Strohbusch S, Reincke M, Feige B, Berger M, Riemann D, Voderholzer U: Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacol, 2002; 27 (6): 1041-1049
  4. Detailinformationen: Transient total sleep loss in cerebral Whipple's disease: a longitudinal study. Voderholzer U, Riemann D, Gann H, Hornyak M, Juengling F, Schumacher M, Reincke M, Von Herbay A, Nishino S, Mignot E, Berger M, Lieb K: Transient total sleep loss in cerebral Whipple's disease: a longitudinal study. J Sleep Res, 2002; 11 (4): 321-329

    Radiologische Universitätsklinik, Abteilung Röntgendiagnostik

  1. Detailinformationen: Subtle prefrontal neuropathology in a pilot magnetic resonance spectroscopy study in patients with borderline personality disorder. van Elst LT, Thiel T, Hesslinger B, Lieb K, Bohus M, Hennig J, Ebert D.: Subtle prefrontal neuropathology in a pilot magnetic resonance spectroscopy study in patients with borderline personality disorder. J Neuropsych Clin N, 2001; 13 (4): 511-514
  2. Detailinformationen: Frontolimbic Brain Abnormalities in Patients with Borderline Personality Disorder. A Volumetric MRI Study. van Elst LT, Hesslinger B, Thiel T, Geiger E, Haegele K, Lemieux L, Lieb K, Bohus M, Hennig J, Ebert D.: Frontolimbic Brain Abnormalities in Patients with Borderline Personality Disorder. A Volumetric MRI Study. Biol Psychiat, 2002 (in Druck)
  3. Detailinformationen: A voxel-based morphometric MRI study in female patients with borderline personality disorder. Rüsch N, van Elst LT, Ludaescher P, Wilke M, Huppertz HJ, Thiel T, Schmahl C, Bohus M, Lieb K, Heßlinger J, Hennig J, Ebert D.: A voxel-based morphometric MRI study in female patients with borderline personality disorder. Neuroimage, 2003; 20 (1): 385-392
  4. Detailinformationen: Frontolimbic Brain Abnormalities in Patients with Borderline Personality Disorder. A Volumetric MRI Study. van Elst LT, Hesslinger B, Thiel T, Geiger E, Haegele K, Lemieux L, Lieb K, Bohus M, Hennig J, Ebert D.: Frontolimbic Brain Abnormalities in Patients with Borderline Personality Disorder. A Volumetric MRI Study. Biol Psychiat, 2003; 54 (2): 163-171
  5. Detailinformationen: Neural correlates of antinociception in borderline personality disorder. Schmahl C, Bohus M, Esposito F, Treede RD, Di Salle F, Greffrath W, Ludaescher P, Jochims A, Lieb K, Scheffler K, Hennig J, Seifritz E.: Neural correlates of antinociception in borderline personality disorder. Arch Gen Psychiat, 2006; 63 (6): 659-667
  6. Detailinformationen: Evidence of disturbed amygdalar energy metabolism in patients with borderline personality disorder. Tebartz van Elst L, Ludaescher P, Thiel T, Büchert M, Hesslinger B, Bohus M, Rüsch N, Hennig J, Ebert D, Lieb K.: Evidence of disturbed amygdalar energy metabolism in patients with borderline personality disorder. Neurosci Lett, 2007; 417 (1): 36-41
  7. Detailinformationen: Inferior frontal white matter microstructure and patterns of psychopathology in women with borderline personality disorder and comorbid attention-deficit hyperactivity disorder. Rusch N, Weber M, Il'yasov KA, Lieb K, Ebert D, Hennig J, Tebartz van Elst L.: Inferior frontal white matter microstructure and patterns of psychopathology in women with borderline personality disorder and comorbid attention-deficit hyperactivity disorder. Neuroimage, 2007; 35 (2): 738-747
  8. Detailinformationen: Early Life Stress: Longitudinal Monitoring of Morphological Impact on the Hippocampus Hsing in Vivo MR-Imaging in Mouse Model. Reichardt W, Gross C, Herpfer I, Haas C, Lieb K, von Elverfeldt D.: Early Life Stress: Longitudinal Monitoring of Morphological Impact on the Hippocampus Hsing in Vivo MR-Imaging in Mouse Model. Proc. 16th Ann Scientific Meeting International Society for Magnetic Resonance in Medicine, 2008: 2307 (16th Ann Scientific Meeting of the International Society for Magnetic Resonance in Medicine (ISMRM), Toronto (03.-09.05.2008))
  9. Detailinformationen: Neurochemical alterations in women with borderline personality disorder and comorbid attention-deficit hyperactivity disorder. Rüsch N, Boeker M, Büchert M, Glauche V, Bohrmann C, Ebert D, Lieb K, Hennig J, Van Elst LT.: Neurochemical alterations in women with borderline personality disorder and comorbid attention-deficit hyperactivity disorder. World J Biol Psychia, 2008: 1-10: http://dx.doi.org/10.1080/15622970801958331 (in Druck)
  10. Detailinformationen: Extraction of prefronto-amygdalar pathways by combining probability maps. Bracht T, Tuscher O, Schnell S, Kreher B, Rusch N, Glauche V, Lieb K, Ebert D, Il'yasov KA, Hennig J, Weiller C, van Elst LT, Saur D.: Extraction of prefronto-amygdalar pathways by combining probability maps. Psychiat Res, 2009; 174 (3): 217-222: http://dx.doi.org/10.1016/j.pscychresns.2009.05.001

    Universitätsklinik für Psychiatrie und Psychosomatik, Abteilung für Psychosomatische Medizin und Psychotherapie

  1. Detailinformationen: Anti-inflammatory substances - a new therapeutic option in Alzheimers's disease Hull M, Fiebich BL, Schumann G, Lieb K, Bauer J: Anti-inflammatory substances - a new therapeutic option in Alzheimers's disease Drug Discov Today, 1999; 4 (6): 275-282
  2. Detailinformationen: The non-steroidal anti-inflammatory drug tepoxalin inhibits interleukin-6 and alpha1-antichymotrypsin synthesis in astrocytes by preventing degradation of IkappaB-alpha. Fiebich BL, Hofer TJ, Lieb K, Huell M, Butcher RD, Schumann G, Schulze-Osthoff K, Bauer J: The non-steroidal anti-inflammatory drug tepoxalin inhibits interleukin-6 and alpha1-antichymotrypsin synthesis in astrocytes by preventing degradation of IkappaB-alpha. Neuropharmacology, 1999; 38 (9): 1325-1333
  3. Detailinformationen: Prefrontal cortical hypometabolism during low-dose interferon alpha treatment Jüngling FD, Ebert D, Gut O, Engelbrecht MA, Rasenack J, Nitzsche EU, Bauer J, Lieb K: Prefrontal cortical hypometabolism during low-dose interferon alpha treatment Psychopharmacology, 2000; 152 (4): 383-389
  4. Detailinformationen: Cognitive impairment in patients with chronic hepatitis treated with low-dose interferon alpha: results from a prospective study. Lieb K, Engelbrecht MA, Gut O, Fiebich BL, Bauer J: Cognitive impairment in patients with chronic hepatitis treated with low-dose interferon alpha: results from a prospective study. ., 2002 (in Druck)
  5. Detailinformationen: Interferon alpha and psychiaric syndromes Schaefer M, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Schmidt F, Grunze H, Lieb K: Interferon alpha and psychiaric syndromes Prog Neuro-psychoph, 2002; 26: 731-746

    Klinik für Neuroradiologie,

  1. Detailinformationen: Transient total sleep loss in cerebral Whipple's disease: a longitudinal study Voderholzer U, Riemann D, Gann H, Hornyak M, Jüngling F, Schumacher M, Reincke M, von Herbay A, Nishino S, Mignot E, Berger M, Lieb K: Transient total sleep loss in cerebral Whipple's disease: a longitudinal study J Sleep Res, 2002; 11: 321-329

    Neurochirurgische Universitätsklinik, Sektion Epileptologie

  1. Detailinformationen: A voxel-based morphometric MRI study in female patients with borderline personality disorder. Rusch N, van Elst LT, Ludaescher P, Wilke M, Huppertz HJ, Thiel T, Schmahl C, Bohus M, Lieb K, Hesslinger B, Hennig J, Ebert D: A voxel-based morphometric MRI study in female patients with borderline personality disorder. Neuroimage, 2003; 20 (1): 385-392

    Universitätsklinik für Psychiatrie und Psychosomatik, Abteilung für Psychiatrie und Psychotherapie im Kindes- und Jugendalter

  1. Detailinformationen: 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline-induced apoptosis in the human neuroblastoma cell line SK-N-SH Akundi RS, Macho A, Munoz E, Lieb K, Bringmann G, Clement HW, Hull M, Fiebich BL: 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline-induced apoptosis in the human neuroblastoma cell line SK-N-SH J Neurochem, 2004; 91 (2): 263-273

    Neurochirurgische Universitätsklinik, Abteilung Allgemeine Neurochirurgie mit Poliklinik

  1. Detailinformationen: No modulatory effect of neurokinin-1 receptor antagonists on serotonin uptake in human and rat brain synaptosomes. Lieb K, Fiebich BL, Herpfer I, Mantovani M, Loffler M, Feuerstein TJ: No modulatory effect of neurokinin-1 receptor antagonists on serotonin uptake in human and rat brain synaptosomes. Eur Neuropsychopharm, 2005; 15 (6): 641-646

    Institut für Psychologie, Abteilung für Sozialpsychologie und Methodenlehre

  1. Detailinformationen: An Intensive Treatment Program of Interpersonal Psychotherapy Plus Pharmacotherapy for Depressed Inpatients: Acute and Long Term Results Schramm E, van Calker D, Dykierek P, Lieb K, Kech S, Zobel I, Leonhart R, Berger, M: An Intensive Treatment Program of Interpersonal Psychotherapy Plus Pharmacotherapy for Depressed Inpatients: Acute and Long Term Results The American Journal of Psychiatry, 2007; 164: 768-777
  2. Detailinformationen: Time course of anger and other emotions in women with borderline personality disorder: A preliminary study. Jacob GA, Guenzler C, Zimmermann S, Scheel CN, Ruesch N, Leonhart R, Nerb J, Lieb K: Time course of anger and other emotions in women with borderline personality disorder: A preliminary study. J Behav Ther Exp Psy, 2008; 39: 391-402

    Institut für Medizinische Biometrie und Medizinische Informatik, Abteilung Medizinische Biometrie und Statistik

  1. Detailinformationen: Predictors of dropout from inpatient dialectical behavior therapy among women with borderline personality disorder. Rüsch N, Schiel S, Corrigan PW, Leihener F, Jacob GA, Olschewski M, Lieb K, Bohus M: Predictors of dropout from inpatient dialectical behavior therapy among women with borderline personality disorder. J Behav Ther Exp Psy, 2008; 39 (4): 497-503: http://dx.doi.org/10.1016/j.jbtep.2007.11.006
  2. Detailinformationen: Pharmacological interventions for borderline personality disorder. Stoffers J, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K: Pharmacological interventions for borderline personality disorder. Cochrane Db Syst Rev, 2010; 6 (online): CD005653: http://dx.doi.org/10.1002/14651858.CD005653.pub2
  3. Detailinformationen: Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM: Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Brit J Psychiat, 2010; 196: 4-12: http://dx.doi.org/10.1192/bjp.bp.108.062984